FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894392370> ?p ?o ?g. }

• W2894392370 endingPage "22" @default.
• W2894392370 startingPage "15" @default.
• W2894392370 abstract "177Lu-PSMA-617 (Lu-PSMA) is an emerging therapy in men with metastatic castration-resistant prostate cancer. Paired theranostic agents have the potential to visually identify phenotypes that will respond to targeted therapy. This study examined the value of 68Ga-HBEDD PSMA-11; prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in predicting treatment response and disease progression in Lu-PSMA therapy within the context of a phase 2 prospective pilot trial.Men with progressive, symptomatic metastatic castration-resistant prostate cancer previously treated with antiandrogens (abiraterone and/or enzalutamide) and taxane-based chemotherapy were prospectively enrolled. Eligibility criteria included uptake on PSMA PET above or equal to liver activity, with no 18F-Fluoro-deoxyglucose (FDG) PET-discordant disease. Men received up to 4 cycles of Lu-PSMA at 6 weekly intervals. Repeat FDG/PSMA PET imaging was performed after completion of therapy or at prostate-specific antigen (PSA) progression. The study assessed treatment response to Lu-PSMA using PSA response and correlated treatment response (PSA) to molecular imaging parameters at enrollment.Fourteen of 18 men screened underwent Lu-PSMA therapy. Ten (71%) of 14 had a PSA response (mean reduction, 59%). A ≥ 50% reduction in PSA occurred in 5 (36%), and ≥ 30% in 9 (64%). PSMA PET standardized uptake value (SUV) at screening was predictive of ≥ 30% PSA reduction: SUV max value 17 ± 9 versus 44 ± 15 (P < .007), and PSMA SUV mean 6 ± 4 versus 10 ± 4 (P < .04). FDG parameters alone, and volume or site of disease did not predict PSA response. No imaging parameters predicted ≥ 50% PSA reduction. Nine of 14 men were reimaged after treatment, revealing 3 distinct patterns of progression.PSMA PET plays an important role in predicting treatment response to Lu-PSMA and in identifying subsequent patterns of failure, which may aid in determining the next best treatment options." @default.
• W2894392370 created "2018-10-05" @default.
• W2894392370 creator A5002877928 @default.
• W2894392370 creator A5006944238 @default.
• W2894392370 creator A5011868052 @default.
• W2894392370 creator A5014807748 @default.
• W2894392370 creator A5023642166 @default.
• W2894392370 creator A5049881119 @default.
• W2894392370 creator A5051929148 @default.
• W2894392370 creator A5053017799 @default.
• W2894392370 creator A5053854599 @default.
• W2894392370 creator A5066214064 @default.
• W2894392370 creator A5071437418 @default.
• W2894392370 creator A5082667412 @default.
• W2894392370 creator A5084855225 @default.
• W2894392370 creator A5085333470 @default.
• W2894392370 creator A5087339643 @default.
• W2894392370 date "2019-02-01" @default.
• W2894392370 modified "2023-10-01" @default.
• W2894392370 title "Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression" @default.
• W2894392370 cites W2014999922 @default.
• W2894392370 cites W2027847537 @default.
• W2894392370 cites W2094108414 @default.
• W2894392370 cites W2105337740 @default.
• W2894392370 cites W2302508993 @default.
• W2894392370 cites W2303817381 @default.
• W2894392370 cites W2304896218 @default.
• W2894392370 cites W2341926107 @default.
• W2894392370 cites W2509471132 @default.
• W2894392370 cites W2515351720 @default.
• W2894392370 cites W2520024435 @default.
• W2894392370 cites W2557995567 @default.
• W2894392370 cites W2596023559 @default.
• W2894392370 cites W2609771428 @default.
• W2894392370 cites W2753761135 @default.
• W2894392370 cites W2769219206 @default.
• W2894392370 cites W2799931007 @default.
• W2894392370 doi "https://doi.org/10.1016/j.clgc.2018.09.014" @default.
• W2894392370 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30425003" @default.
• W2894392370 hasPublicationYear "2019" @default.
• W2894392370 type Work @default.
• W2894392370 sameAs 2894392370 @default.
• W2894392370 citedByCount "123" @default.
• W2894392370 countsByYear W28943923702018 @default.
• W2894392370 countsByYear W28943923702019 @default.
• W2894392370 countsByYear W28943923702020 @default.
• W2894392370 countsByYear W28943923702021 @default.
• W2894392370 countsByYear W28943923702022 @default.
• W2894392370 countsByYear W28943923702023 @default.
• W2894392370 crossrefType "journal-article" @default.
• W2894392370 hasAuthorship W2894392370A5002877928 @default.
• W2894392370 hasAuthorship W2894392370A5006944238 @default.
• W2894392370 hasAuthorship W2894392370A5011868052 @default.
• W2894392370 hasAuthorship W2894392370A5014807748 @default.
• W2894392370 hasAuthorship W2894392370A5023642166 @default.
• W2894392370 hasAuthorship W2894392370A5049881119 @default.
• W2894392370 hasAuthorship W2894392370A5051929148 @default.
• W2894392370 hasAuthorship W2894392370A5053017799 @default.
• W2894392370 hasAuthorship W2894392370A5053854599 @default.
• W2894392370 hasAuthorship W2894392370A5066214064 @default.
• W2894392370 hasAuthorship W2894392370A5071437418 @default.
• W2894392370 hasAuthorship W2894392370A5082667412 @default.
• W2894392370 hasAuthorship W2894392370A5084855225 @default.
• W2894392370 hasAuthorship W2894392370A5085333470 @default.
• W2894392370 hasAuthorship W2894392370A5087339643 @default.
• W2894392370 hasConcept C121608353 @default.
• W2894392370 hasConcept C126322002 @default.
• W2894392370 hasConcept C143998085 @default.
• W2894392370 hasConcept C151730666 @default.
• W2894392370 hasConcept C188816634 @default.
• W2894392370 hasConcept C199374082 @default.
• W2894392370 hasConcept C20417620 @default.
• W2894392370 hasConcept C2775842073 @default.
• W2894392370 hasConcept C2776235491 @default.
• W2894392370 hasConcept C2776551883 @default.
• W2894392370 hasConcept C2777511904 @default.
• W2894392370 hasConcept C2779343474 @default.
• W2894392370 hasConcept C2780192828 @default.
• W2894392370 hasConcept C2989005 @default.
• W2894392370 hasConcept C530470458 @default.
• W2894392370 hasConcept C61367390 @default.
• W2894392370 hasConcept C71924100 @default.
• W2894392370 hasConcept C86803240 @default.
• W2894392370 hasConceptScore W2894392370C121608353 @default.
• W2894392370 hasConceptScore W2894392370C126322002 @default.
• W2894392370 hasConceptScore W2894392370C143998085 @default.
• W2894392370 hasConceptScore W2894392370C151730666 @default.
• W2894392370 hasConceptScore W2894392370C188816634 @default.
• W2894392370 hasConceptScore W2894392370C199374082 @default.
• W2894392370 hasConceptScore W2894392370C20417620 @default.
• W2894392370 hasConceptScore W2894392370C2775842073 @default.
• W2894392370 hasConceptScore W2894392370C2776235491 @default.
• W2894392370 hasConceptScore W2894392370C2776551883 @default.
• W2894392370 hasConceptScore W2894392370C2777511904 @default.
• W2894392370 hasConceptScore W2894392370C2779343474 @default.
• W2894392370 hasConceptScore W2894392370C2780192828 @default.
• W2894392370 hasConceptScore W2894392370C2989005 @default.
• W2894392370 hasConceptScore W2894392370C530470458 @default.

• next